Judith Evelyn Raber-Durlacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7899397/publications.pdf

Version: 2024-02-01

26 papers 1,290 citations

16 h-index 26 g-index

27 all docs

27 docs citations

times ranked

27

1656 citing authors

#	Article	IF	CITATIONS
1	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Supportive Care in Cancer, 2016, 24, 2781-2792.	2.2	179
2	Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Supportive Care in Cancer, 2016, 24, 2793-2805.	2.2	169
3	Oral Mucositis Induced By Anticancer Therapies. Current Oral Health Reports, 2015, 2, 202-211.	1.6	134
4	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	4.4	112
5	Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncology, 2016, 54, 7-14.	1.5	92
6	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	4.4	82
7	Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Supportive Care in Cancer, 2012, 20, 3231-3240.	2.2	75
8	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQâ€HN43: Phase IV. Head and Neck, 2019, 41, 1725-1737.	2.0	69
9	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	4.4	51
10	Safety and efficacy of photobiomodulation therapy in oncology: A systematic review. Cancer Medicine, 2020, 9, 8279-8300.	2.8	49
11	Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. Mediators of Inflammation, 2014, 2014, 1-14.	3.0	48
12	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2020, 28, 2485-2498.	2.2	42
13	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 95, 191-213.	4.4	33
14	Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients. Scientific Reports, 2019, 9, 16929.	3.3	32
15	Photobiomodulation therapy in the management of chronic oral graft-versus-host disease. Supportive Care in Cancer, 2017, 25, 357-364.	2.2	23
16	The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy. Supportive Care in Cancer, 2019, 27, 3667-3679.	2.2	18
17	Impact of Oral Side Effects from Conditioning Therapy Before Hematopoietic Stem Cell Transplantation: Protocol for a Multicenter Study. JMIR Research Protocols, 2018, 7, e103.	1.0	18
18	Role of Photobiomodulation Therapy in Neurological Primary Burning Mouth Syndrome. A Systematic Review and Meta-Analysis of Human Randomised Controlled Clinical Trials. Pharmaceutics, 2021, 13, 1838.	4.5	16

#	Article	IF	CITATIONS
19	Photobiomodulation effects on head and neck squamous cell carcinoma (HNSCC) in an orthotopic animal model. Supportive Care in Cancer, 2020, 28, 2721-2727.	2.2	10
20	Chronic oral graft-versus-host disease: induction and maintenance therapy with photobiomodulation therapy. Supportive Care in Cancer, 2021, 29, 1387-1394.	2.2	9
21	Long-Term Analysis of Resilience of the Oral Microbiome in Allogeneic Stem Cell Transplant Recipients. Microorganisms, 2022, 10, 734.	3.6	8
22	Exploring the role of oral microorganisms in the pathogenesis of mucositis by assessing their impact on metabolic activity and reproductive capacity of epithelial cells in vitro. Supportive Care in Cancer, 2020, 28, 4729-4735.	2.2	7
23	Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2). Cancers, 2022, 14, 3379.	3.7	7
24	Oral health–related quality of life of patients with oral chronic graft-versus-host disease. Supportive Care in Cancer, 2021, 29, 6353-6360.	2,2	3
25	Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. Quality of Life Research, 2022, 31.841-853.	3.1	3
26	Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib. Genes, 2022, 13, 1198.	2.4	1